Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/11/2024 | $115.00 | Overweight | KeyBanc Capital Markets |
| 7/10/2024 | $100.00 | Outperform | Leerink Partners |
| 3/6/2024 | $95.00 | Overweight | Barclays |
| 3/14/2023 | $57.00 | Equal Weight | Barclays |
| 2/7/2022 | $90.00 → $80.00 | Strong Buy | Raymond James |
| 11/3/2021 | $94.00 → $80.00 | Buy | Mizuho |
| 11/2/2021 | $107.00 → $90.00 | Strong Buy | Raymond James |
| 10/13/2021 | $100.00 → $88.00 | Buy | Truist Securities |
4 - Encompass Health Corp (0000785161) (Issuer)
KeyBanc Capital Markets initiated coverage of Encompass Health with a rating of Overweight and set a new price target of $115.00
Leerink Partners initiated coverage of Encompass Health with a rating of Outperform and set a new price target of $100.00
Barclays initiated coverage of Encompass Health with a rating of Overweight and set a new price target of $95.00
8-K - Encompass Health Corp (0000785161) (Filer)
8-K - Encompass Health Corp (0000785161) (Filer)
10-Q - Encompass Health Corp (0000785161) (Filer)